Connect with us

International

TWOH is our New SUB-PENNY Alert – back to kick-off Fall & take on Instacart!

TWO HANDS CORPORATION US SYMBOL: TWOH Last Price: .004  |  Website  |  Latest News Today we kick-off another Explosive Fall Season with one of the most exciting companies on the market Today trading at mere SUB-PENNY prices! Now in case you haven’t…

Published

on


TWO HANDS CORPORATION

US SYMBOL: TWOH
Last Price: .004  |  Website  |  Latest News

Today we kick-off another Explosive Fall Season with one of the most exciting companies on the market Today trading at mere SUB-PENNY prices!

Now in case you haven’t traded a Sub-Penny before, these are stocks that are trading below .01 and many have a tendency to catch fire and make big moves quickly due to their ultra-low price.

And Today’s New Alert may be no different!

This is a past-winning stock that has seen at least THREE Triple-Digit Gaining Rallies in just the last 2 months alone and in the midst of yet another potential BREAKOUT as I write!

And that’s because the Street is completely hot on what this company is doing and the Sector it’s in.

It shouldn’t surprise anyone that Food Delivery apps from DoorDash (NYSE: DASH) to Uber Eats (NYSE: UBER) to GrubHub/Shipt (NYSE: GRUB) saw record food deliveries and RECORD GROWTH over the course of the Pandemic.

Popular grocery delivery company, Instacart sold $700 MIL worth of groceries per week in the first two weeks of last April. This was an amazing increase of 450% from December that required hundreds of thousands of more workers to keep up with the overwhelming demand!

As millions of people shelter at home, demand for grocery delivery has exploded, with an estimated one-third of shoppers buying groceries online, according to a survey. And no one expects this trend to change…

42% of American shoppers and 43% of Europeans said the COVID-19 crisis had changed their food and beverage purchasing habits, according to a Bazaarvoice survey.

And while lockdown rules may have been relaxed in the US, it is still present in many other countries, including our neighbor to the north – Canada.

Seizing on this opportunity is Today’s New Alert – a company looking to dominate the food delivery scene in Canada and is already making it’s mark in it’s largest city of Toronto!

WE ARE ISSUING AN IMMEDIATE ALERT ON TWOH!

Two Hands Corporation (TWOH) is a custom application development company with proven numerous technological competencies in digital technologies.

gocart

At focus is GOCART.CITY – a division of TWOH is an online grocery delivery marketplace that services the Greater Toronto Area. They curate and deliver the freshest produce and specialty foods in Southern Ontario.

We are in a new evolutionary stage of grocery shopping and Two Hands Corporation (OTC: TWOH) could see it’s Biggest year yet in 2021!

So could another BREAKOUT be imminent?  Let’s check the charts….

TWOH ON A BULLISH PATH TO NEW HIGHS?
There’s no denying TWOH has been quite the moneymaker for traders this year.

In just the last 2 months alone, TWOH has managed THREE Triple-Digit Rallies as you can see on the chart below…

Now in the midst of another rally with multiple BULLISH signals, could a move back to 52-week highs and beyond be IMMINENT?  Take a look…

chart

As you can see above, TWOH is currently on it’s third Bullish run in the last 2 months as it makes higher highs and our 50 and 200 Day Moving Average near convergence.

Top that off with our RSI Indicator now trending in the POWER ZONE (not oversold or overbought) and our MACD Indicator crossing the 0.0 level CONFIRMING Bullish Divergence and we may have a recipe for a continued run!

Keep in mind, a return to 52 Week Highs of .0097 gives TWOH up to 142% UPSIDE POTENTIAL!

On our side are FOUR BUY/BULLISH Ratings:

buy

Investing.com currently gives TWOH it’s top rating of “STRONG BUY” on the Daily chart!
Barchart.com currently gives TWOH a “BUY” Rating!
AmericanBulls.com currently gives TWOH a “STAY LONG” Rating
StockTA.com currently gives TWOH a “BULLISH” Rating

So what could take this rally to the next level? Read on….

TWOH – BRINGING YOUR GROCERIES TO YOUR DOORSTEP
2020-2021 were banner years for TWOH.

Pivoting out of the Cannabis industry, the company introduced it’s new division, GOCART.CITY, an innovative service that delivers fresh produce and groceries to your door in Canada.

gocart

Toronto residents have been in lockdown since November.

In January, GoCart.city expanded its delivery areas to help serve communities that were unable to receive grocery delivery. In addition to their current delivery areas: Toronto, Mississauga, Etobicoke, Oakville, Burlington, Brampton, Georgetown, and more.

Consumers in Ontario can shop GoCart.city’s wide selection of items including fresh and high quality produce, meat, frozen goods, bakery and pastry, gluten-free organic items, and much more at www.gocart.city or using the GoCart.city Android or iOS app. The online grocery retailer offers quick delivery, free shipping over $25, and great prices on everyday items with no price markups or hidden fees.

app
app

The demand for home deliveries of groceries has exploded in recent months, and GoCart aims to satisfy the fast-growing demand.

GoCart offers timely, next day, deliveries, unlike many company’s, which offer limited options, GoCart offers anything from specialty products to food staples—straight to your door.

Recently rolling out Saturday deliveries, TWOH’s GoCart operates 7 days a week from 8am to 8pm on your selected delivery day. GoCart is already equipped to handle deliveries to many neighborhoods, and that’s just the beginning….

GoCart Saves Time

The average person spends about 130 hours a year at the grocery store— about 2.5 hours per week. The average time spent on a weekly online grocery shop is 15 minutes. Do the math…

GoCart Saves Money

Now we can’t talk time without talking money. About 20% of people believe that shopping for groceries online definitely saves them money— in reality, the savings are probably much higher than many people realize.

Time is money. Not having to drive to the store several times a month can free up about $640 USD in extra productivity, give or take. When it comes to more concrete measurements, we save an extra $100 USD plus monthly by not paying for the extra gas or grabbing unnecessary impulse purchases.

GoCart Makes Eating Healthier Easier

With more data available than ever regarding what constitutes a healthy meal, people are now more health conscious than ever. This is probably why nearly 90 percent of Canadians cook dinner at home three or four times a week. And the top reason for not cooking at home? Canadians who don’t prepare their own meals claim they’re too busy.

Shopping for groceries online not only encourages busy people to cook at home, but it removes many of the temptations found at the store. Another added perk? You have more time to analyze nutrition labels, instead of feeling rushed to get through your list and get out.

TWOH’S OTHER UNIQUE ENDEAVORS

twohands

TWOH is also behind the Two Hands Appa co-parenting app designed to make co-parenting easier and was built for parents that are separated/divorced who need a helping hand when it comes to managing life around their children.

After years of collaborating with fellow parents and co-parents, and through the help of their designers and programmers, “Two Hands” was conceived. Imagine having a tool that lets both father and mother have access to all of their children’s information, and appointments in ONE place.

“Two Hands” is accessed primarily through the web which makes it easier to connect to people and manage one or two households at the same time but the company has also made it possible for the application to be accessed from all kinds of devices such as smart phones.

Check out THIS VIDEO to get the full picture of this groundbreaking app for parents!

two hands gone

The Two Hands Gone app allows you to send encrypted text messages right from your phone, combining military-grade security, confidentiality, and privacy

Up until now, messaging app security has been weak. Before Two Hands Gone, all it took was having a tech savvy friend or watching some video tutorials to learn how to crack these apps.

With Two Hands Gone:
  All text messages are asymmetrically encrypted
  Safe with keys that only YOU own
  Message Auto-Deletion after being read
  No preview. You must click to view the message
  Screen Capture disabled

WHAT’S NEXT FOR TWOH?
TWOH is now in the process of expanding it’s GoMeal Kits selection which are essentially fully prepared meal kits by Executive Chef Grace Di Fede.

“GoMeal offer a variety of contemporary, nutritious quick and easy to follow recipes, with a focus on, local and imported ingredients.”, commented Executive Chef Grace Di Fede. “We are continually expanding our GoMeal selections and have added our new GoParent Kits designed for on the parents and kids On The GO.”

TWOH also announced it will be expanding it’s focus on two new segments of their business…

Grocery Originals: a brick-and-mortar retail experience that was recently launched in Mississauga, Ontario, fully equipped with a deli, cold storage, and a stone pizza oven. We will also be offering a wide variety of fresh and specialty meals curated by Corporate Executive Chef, Grace Di Fede.

Cuore Food Services: a food import and distribution brand that operates in a wide range of channels including food service, retail chains, hotels, and restaurants. Core offerings from Cuore range from Italian themed oils, pastas, sauces, to dry packed goods, to exclusive wines, coffees, and desserts.

THE BOTTOM LINE
if you don’t believe there is a true paradigm shift in the works regarding the way people shop…FORGET THIS EMAIL.

But if you believe the next evolution of shopping, especially for groceries, will continue to be done online….TWOH MUST NOT BE IGNORED!

With the company rapidly expanding throughout the Toronto Metro area and Ontario + moving to 7 Day/week deliveries to due demand….

TWOH could be the single most important stock you’ll ever watch at SUB-PENNY prices!!

So with a BULLISH CHART coiling, Multiple BUY/BULLISH Ratings and TRIPLE DIGIT UPSIDE, make sure you put TWOH on your screen RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!

Good Trading,

Xavier Wright
Editor | WallStreetAlerts.org


Still need an Online Broker to place trades?
RobinHood & WeBull do NOT work!
Tradestation
Our Analysts HIGHLY recommend TRADESTATION!

text alerts

.

IO

Home  |  Trading School  |  Twitter  |  ContactUNSUBSCRIBEView in Browser

Disclaimer2

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

COMPENSATION: WallStreetAlerts.org has been compensated seventy-five thousand dollars cash via bank wire by a third party, Awareness Consulting Network LLC for a one day Two Hands Corp. marketing services contract.  WallStreetAlerts.org does not own any shares of TWOH. WallStreetAlerts.org has been previously compensated one hundred thousand dollars cash via bank wire by a third party, Awareness Consulting Network LLC for a two day Two Hands Corp. marketing services contract which has expired. WallStreetAlerts.org does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

Disclaimer1

Read More

Continue Reading

International

John Lewis relies too heavily on its heritage – here’s what it could do instead

The company has returned to profit by making cuts, but there are things it could do to reinvent itself.

Published

on

By

Road to recovery? Jevanto Productions/Shutterstock

In a tricky economic climate, the British department store John Lewis has managed to deliver some good news. The retail partnership – owned by its 80,000 employees – posted pre-tax profits of £56 million after a £234 million loss the year before.

The positive announcement was somewhat tarnished by the fact that those employees (known as partners) would not receive a bonus for the second year in a row. There were also hints of job cuts.

But what more could this giant of UK retail, which also owns Waitrose supermarkets, do to endure its survival? Does its increasing reliance on grocery sales mean its own brand has become less valuable?

For over 160 years on the high street, John Lewis has worked hard on that brand. Its slogan (scrapped in 2022) about being “never knowingly undersold” was well known, it remains a trusted supplier of an extensive range of household hoods, rates highly for customer service, and runs Christmas TV adverts which have became a media event in themselves.

In doing all of those things, John Lewis seemed to be in a much better place than its rivals. BHS (founded in 1928) and Debenhams (1778) have disappeared from the high street. House of Fraser (1849) was taken over and has a much-reduced physical presence.

John Lewis’s nearest rival, Marks & Spencer (1884), is now doing well, but only after it underwent a fairly brutal restructuring which involved cutting thousands of jobs during the pandemic, closing 67 stores, and slashing its operations in France.

So John Lewis’s “brand heritage” – its history, tradition and pedigree – has worked pretty well for a pretty long time. But its recent return to profit was the combined effort of reinvesting and streamlining, according to some reports.

Also known as “trimming the fat” in the business world, the retailer’s streamlining endeavours consisted of cutting more than 1,500 jobs, and closing underperforming stores, such as the branch in Sheffield, which had served residents for nearly 80 years and was much mourned, including by my own mother-in-law.

It has also been reported that more job cuts are imminent, with up to 11,000 jobs to go in the next five years.

And perhaps these measures highlight some of the harsh realities of running a department store in the always-open and effortless world of online shopping. Maybe employees (even those considered partners, as under John Lewis’s employee-ownership model) have become expendable.

Maybe physical stores, where consumers go to explore and seek advice, have become expendable. Maybe all traditions are expendable when they are not commercially viable.

People first

Yet the world of retail is filled with examples of heritage brands reinventing themselves to stay relevant, buoyant and competitive.

John Lewis will need to do the same if it wants to retain its legacy on the British high street. And it could do worse than taking a leaf out of Waitrose’s playbook.

For the company’s return to profit was largely due to the buoyant sales generated by Waitrose supermarkets, which increased by 4%. The department store business meanwhile, suffered a 2% fall.

Part of Waitrose’s success comes from providing a sense of indulgence and enjoyment – including healthy food – through carefully curated and often locally sourced products. It works closely with local farmers, supports regional suppliers (an approach that has also contributed to M&S’s success), and reinvests in stores and product offers.

Essentially, as part of UK’s grocery sector, Waitrose extended its partnership ethos to include people and groups beyond the shop walls – to build a “local retail ecosystem” that promotes and leverages a community spirit around their stores.

M&S shop front.
Appealing to appetites. Simon Vayro/Shutterstock

John Lewis department stores could try and do something similar. They could focus more on products that help customers live healthier and more active lives, and which are relevant to their interests. They could sell products created by local small businesses, and make a determined approach to be a supportive presence in the regions they serve.

Research suggests that heritage brands benefit from having a moral standing – when they show they care about the people they make money from, the local communities they operate in, and the people they employ.

So perhaps John Lewis should make moral values a part of its evolving heritage. It needs to show it cares not just for the people who work for the company directly, but also the people on whom it relies for success – the customers – and people it can build new relationships with. All of them could prove critical to its future success.

Kokho Jason Sit is affiliated with the Chartered Institute of Marketing.

Read More

Continue Reading

International

AI can help predict whether a patient will respond to specific tuberculosis treatments, paving way for personalized care

People have been battling tuberculosis for thousands of years, and drug-resistant strains are on the rise. Analyzing large datasets with AI can help humanity…

Published

on

By

Tuberculosis typically infects the lungs but can spread to the rest of the body. stockdevil/iStock via Getty Images Plus

Tuberculosis is the world’s deadliest bacterial infection. It afflicted over 10 million people and took 1.3 million lives in 2022. These numbers are predicted to increase dramatically because of the spread of multidrug-resistant TB.

Why does one TB patient recover from the infection while another succumbs? And why does one drug work in one patient but not another, even if they have the same disease?

People have been battling TB for millennia. For example, researchers have found Egyptian mummies from 2400 BCE that show signs of TB. While TB infections occur worldwide, the countries with the highest number of multidrug-resistant TB cases are Ukraine, Moldova, Belarus and Russia.

The COVID-19 pandemic set back progress in addressing many health conditions, including TB.

Researchers predict that the ongoing war in Ukraine will result in an increase in multidrug-resistant TB cases because of health care disruptions. Additionally, the COVID-19 pandemic reduced access to TB diagnosis and treatment, reversing decades of progress worldwide.

Rapidly and holistically analyzing available medical data can help optimize treatments for each patient and reduce drug resistance. In our recently published research, my team and I describe a new AI tool we developed that uses worldwide patient data to guide more personalized and effective treatment of TB.

Predicting success or failure

My team and I wanted to identify what variables can predict how a patient responds to TB treatment. So we analyzed more than 200 types of clinical test results, medical imaging and drug prescriptions from over 5,000 TB patients in 10 countries. We examined demographic information such as age and gender, prior treatment history and whether patients had other conditions. Finally, we also analyzed data on various TB strains, such as what drugs the pathogen is resistant to and what genetic mutations the pathogen had.

Looking at enormous datasets like these can be overwhelming. Even most existing AI tools have had difficulty analyzing large datasets. Prior studies using AI have focused on a single data type – such as imaging or age alone – and had limited success predicting TB treatment outcomes.

We used an approach to AI that allowed us to analyze a large and diverse number of variables simultaneously and identify their relationship to TB outcomes. Our AI model was transparent, meaning we can see through its inner workings to identify the most meaningful clinical features. It was also multimodal, meaning it could interpret different types of data at the same time.

Microscopy image of rod-shaped TB bacteria stained green
Mycobacterium tuberculosis spreads through aerosol droplets. NIAID/NIH via Flickr

Once we trained our AI model on the dataset, we found that it could predict treatment prognosis with 83% accuracy on newer, unseen patient data and outperform existing AI models. In other words, we could feed a new patient’s information into the model and the AI would determine whether a specific type of treatment will either succeed or fail.

We observed that clinical features related to nutrition, particularly lower BMI, are associated with treatment failure. This supports the use of interventions to improve nourishment, as TB is typically more prevalent in undernourished populations.

We also found that certain drug combinations worked better in patients with certain types of drug-resistant infections but not others, leading to treatment failure. Combining drugs that are synergistic, meaning they enhance each other’s potency in the lab, could result in better outcomes. Given the complex environment in the body compared with conditions in the lab, it has so far been unclear whether synergistic relationships between drugs in the lab hold up in the clinic. Our results suggest that using AI to weed out antagonistic drugs, or drugs that inhibit or counteract each other, early in the drug discovery process can avoid treatment failures down the line.

Ending TB with the help of AI

Our findings may help researchers and clinicians meet the World Health Organization’s goal to end TB by 2035, by highlighting the relative importance of different types of clinical data. This can help prioritize public health efforts to mitigate TB.

While the performance of our AI tool is promising, it isn’t perfect in every case, and more training is needed before it can be used in the clinic. Demographic diversity can be high within a country and may even vary between hospitals. We are working to make this tool more generalizable across regions.

Our goal is to eventually tailor our AI model to identify drug regimens suitable for individuals with certain conditions. Instead of a one-size-fits-all treatment approach, we hope that studying multiple types of data can help physicians personalize treatments for each patient to provide the best outcomes.

Sriram Chandrasekaran receives funding from the US National Institutes of Health.

Read More

Continue Reading

International

IVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets

  Credit: IVI IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international…

Published

on

 

Credit: IVI

  • IVI will complete the technology transfer by 2025
  • Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international markets

 

March 20, 2024, SEOUL, Republic of Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, today announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company.

 

Following the signing of a technology license agreement in November last year, IVI has begun providing the technical information, know-how, and materials to produce OCV-S at BE facilities and will continue to support necessary clinical development and regulatory approvals. IVI and BE entered this partnership during an unprecedented surge of cholera outbreaks worldwide and aim to increase the volume of low-cost cholera vaccine in India as well as the global public market.

 

IVI will complete the technology transfer by 2025 and the oral cholera vaccine will be manufactured for India and international markets by Biological E. Limited.

 

Dr. Jerome Kim, Director General of IVI, said: “In an era of heightened risk of poverty-associated infectious diseases such as cholera, the world needs a sustainable source of high-quality, affordable vaccines and committed manufacturers to supply them. We are pleased to partner with Biological E., a company with a proven history of making life-saving vaccines accessible globally, to address this supply gap and protect communities from this deadly, though preventable, disease.”

 

Ms. Mahima Datla, Managing Director, Biological E. Limited, said: “We are glad to be in collaboration with IVI for the manufacture of simplified Oral Cholera Vaccine. Our efforts are aimed to not only combat the disease but to also be part of a sustained legacy of innovation, collaboration, and health stewardship. Together with IVI, we are happy to be shaping a healthier and more resilient future by making this vaccine accessible globally.”

 

This technology transfer and licensing agreement is the sixth of its kind for IVI, transferring such technology to manufacturers in India, the Republic of Korea, Bangladesh, and South Africa. All these partnerships have led to or seek to achieve, pre-qualification (PQ) from the World Health Organization, a designation that enables global agencies such as UNICEF to procure the vaccine for the global market. BE already has 9 vaccines with WHO PQ in its portfolio, and IVI and BE will pursue WHO PQ for OCV-S as well, following national licensure in India.

 

Dr. Julia Lynch, Director of IVI’s Cholera Program, said: “The cholera situation is dire, and the availability and use of oral cholera vaccine is an essential part of a multifaceted approach to cholera control and prevention, especially as outbreaks increase and the global vaccine supply remains strained. With more manufacturers like BE entering the market, the future supply situation looks strong. IVI remains committed to ensuring the availability of the oral cholera vaccine and to developing new and improved vaccines that are equally safe, effective, and affordable and made around the world, for the world.”

 

OCV-S is a simplified formulation of OCV with the potential to lower production costs while increasing production capacity for current and aspiring OCV manufacturers. IVI’s development of OCV-S and ongoing technology transfers are part of an institutional strategy to confront cholera with 3 main goals: 1) Ensure supply of OCV 2) Improve cholera vaccines 3) Support OCV use and introduction. The Bill & Melinda Gates Foundation has been supporting IVI’s cholera program since 2000 and is funding this latest technology transfer to BE.

 

###

 

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

 

About Biological E. Limited

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to more than 130 countries and its therapeutic products are sold in India, the USA and Europe. BE currently has 8 WHO-prequalified vaccines and 10 USFDA approved Generic Injectables in its portfolio. Recently, BE has received Emergency Use Listing (EUL) from the WHO for CORBEVAX®, the COVID-19 vaccine. Recently, DCGI has approved BE’S 14-Valent Pneumococcal Conjugate vaccine.

In recent years, BE has embarked on new initiatives for organizational expansion such as developing specialty injectable products for global markets as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

Please follow us on Facebook, LinkedIn and Twitter

 

 

MEDIA CONTACTS

IVI

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int

 

Biological E. Limited

K. Vijay Amruth Raj
Email: Vijay.Kammari@biologicale.com
www.biologicale.com/news


Read More

Continue Reading

Trending